Amgen (AMGN) Stock Price, News & Analysis

Company Overview

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Founded in 1980 as Applied Molecular Genetics, Amgen pioneered the development of human therapeutics through advances in recombinant DNA and cellular biology. The company focuses on discovering, developing and manufacturing biologic medicines that address serious illnesses in areas such as oncology, inflammation, bone health, cardiovascular disease and nephrology.

Amgen’s commercial portfolio includes several widely prescribed biologics. Neulasta (pegfilgrastim) helps reduce the incidence of infection in patients undergoing chemotherapy, while Enbrel (etanercept) treats autoimmune conditions such as rheumatoid arthritis and psoriasis. Prolia and Xgeva (both denosumab) are therapies for bone-related diseases, and Repatha (evolocumab) is used to manage high cholesterol in patients at risk of cardiovascular events. The company continues to advance its pipeline with novel candidates in oncology, hematology and rare diseases.

Serving patients in more than 100 countries, Amgen maintains research, development and manufacturing facilities in North America, Europe and the Asia-Pacific region. Key production sites include biologics manufacturing plants in Puerto Rico and Ireland, complemented by R&D centers in California and Cambridge, Massachusetts. Amgen combines internal innovation with strategic collaborations and partnerships to accelerate the translation of scientific discoveries into new therapies.

Leadership at Amgen is anchored by Robert A. Bradway, who serves as chairman and chief executive officer. Under his tenure, the company has emphasized precision medicine, operational excellence and sustainability initiatives designed to improve global access to biotherapeutics. Amgen continues to invest heavily in research and development to expand its portfolio and meet evolving patient needs worldwide.

Key Stats

• Today's Range: $294.56 to $297.63
• 50-Day Range: $271.18 to $301.94
• 52-Week Range: $253.30 to $335.88
• Volume: 840,376 shs
• Average Volume: 2.78 million shs
• Market Capitalization: $158.97 billion
• P/E Ratio: 24.15
• Dividend Yield: 3.22%
• Price Target: $309.42
• Consensus Rating: Hold

Amgen Stock Analysis - MarketRank™

Amgen scored higher than 91% of companies evaluated by MarketBeat, and ranked 89th out of 942 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.5 / 5
• Analyst Rating: Hold

Consensus Rating

Amgen has received a consensus rating of Hold. The company's average rating score is 2.30, and is based on 7 buy ratings, 12 hold ratings, and 1 sell rating.

Upside/Downside

The consensus price target for Amgen is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Amgen has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 3.73%

Earnings Growth

Earnings for Amgen are expected to grow by 3.73% in the coming year, from $20.62 to $21.39 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Amgen is 24.19, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 234.08.

Price to Earnings Ratio vs. Sector

The P/E ratio of Amgen is 24.19, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 85.72.

Price to Earnings Growth Ratio

Amgen has a PEG Ratio of 2.55. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Amgen has a P/B Ratio of 27.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

2.46% of the float of Amgen has been sold short.

Short Interest Ratio / Days to Cover

Amgen has a short interest ratio ("days to cover") of 5.9.

Change versus previous month

Short interest in Amgen has recently increased by 11.86%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 3.3 / 5
• Dividend Strength: Strong

Dividend Yield

Amgen pays a meaningful dividend of 3.24%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Amgen has been increasing its dividend for 14 years.

Dividend Coverage

The dividend payout ratio of Amgen is 77.84%. Payout ratios above 75% are not desirable because they may not be sustainable.

Dividend Sustainability

Based on earnings estimates, Amgen will have a dividend payout ratio of 44.51% next year. This indicates that Amgen will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: 3.9 / 5
• Environmental Score: -2.42

Percentage of Shares Shorted

2.46% of the float of Amgen has been sold short.

Short Interest Ratio / Days to Cover

Amgen has a short interest ratio ("days to cover") of 5.9.

Change versus previous month

Short interest in Amgen has recently increased by 11.86%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 4.0 / 5
• News Sentiment: 1.12

News Sentiment

Amgen has a news sentiment score of 1.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 58 news articles for Amgen this week, compared to 27 articles on an average week.

Search Interest

58 people have searched for AMGN on MarketBeat in the last 30 days. This is an increase of 45% compared to the previous 30 days.

MarketBeat Follows

29 people have added Amgen to their MarketBeat watchlist in the last 30 days. This is an increase of 383% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Amgen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $376,286.00 in company stock.

Percentage Held by Insiders

Only 0.69% of the stock of Amgen is held by insiders.

Percentage Held by Institutions

76.50% of the stock of Amgen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

AMGN Stock Analysis - Frequently Asked Questions

How have AMGN shares performed this year?

Amgen's stock was trading at $260.64 on January 1st, 2025. Since then, AMGN stock has increased by 13.2% and is now trading at $295.1550.

How were Amgen's earnings last quarter?

Amgen Inc. (NASDAQ:AMGN) announced its earnings results on Tuesday, August, 5th. The medical research company reported $6.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.28 by $0.74. The company's revenue was up 9.4% on a year-over-year basis.
Read the conference call transcript.

Does Amgen have any subsidiaries?

Amgen subsidiaries include TeneoBio, Five Prime Therapeutics, Rodeo Therapeutics, Otezla, Nuevolution, Catherex, Catherex, and more.

Who are Amgen's major shareholders?

Amgen's top institutional investors include Assenagon Asset Management S.A. (0.04%), Aaron Wealth Advisors LLC (0.03%), Czech National Bank (0.03%) and ST Germain D J Co. Inc. (0.02%). Insiders that own company stock include Amgen Inc, Murdo Gordon, David M Reese, Jonathan P Graham, Rachna Khosla, Nancy A Grygiel and Nancy A Grygiel.
View institutional ownership trends.

How do I buy shares of Amgen?

Shares of AMGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Amgen own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Amgen investors own include NVIDIA (NVDA), Meta Platforms (META), Chevron (CVX), Verizon Communications (VZ), Bristol Myers Squibb (BMY), JPMorgan Chase & Co. (JPM) and Advanced Micro Devices (AMD).

Company Calendar

• Last Earnings: 8/05/2025
• Record date for 9/12 Dividend: 8/22/2025
• Ex-Dividend for 9/12 Dividend: 8/22/2025
• Dividend Payable: 9/12/2025
• Today: 10/08/2025
• Next Earnings (Estimated): 11/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:AMGN
• CIK: 318154
• Web: www.amgen.com
• Phone: (805) 447-1000
• Fax: 805-447-1010
• Employees: 28,000
• Year Founded: 1980

Price Target and Rating

• Average Price Target for Amgen: $309.42
• High Price Target: $383.00
• Low Price Target: $195.00
• Potential Upside/Downside: +4.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.30
• Research Coverage: 20 Analysts

Profitability

• EPS (Trailing Twelve Months): $12.23
• Trailing P/E Ratio: 24.31
• Forward P/E Ratio: 14.41
• P/E Growth: 2.55
• Net Income: $4.09 billion
• Net Margins: 18.96%
• Pretax Margin: 21.26%
• Return on Equity: 174.71%
• Return on Assets: 13.12%

Debt

• Debt-to-Equity Ratio: 7.24
• Current Ratio: 1.31
• Quick Ratio: 0.98

Sales & Book Value

• Annual Sales: $33.42 billion
• Price / Sales: 4.79
• Cash Flow: $30.70 per share
• Price / Cash Flow: 9.68
• Book Value: $10.93 per share
• Price / Book: 27.19

Miscellaneous

• Outstanding Shares: 538,360,000
• Free Float: 534,647,000
• Market Cap: $160.00 billion
• Optionable: Optionable
• Beta: 0.49